P Lennon1, S Deady2, N White3, D Lambert3, M L Healy4, A Green3, J Kinsella5, C Timon5, J P O' Neill6. 1. Department of Otolaryngology, Head and Neck Surgery, St. James's Hospital, Dublin 8, Ireland. paullennon81@gmail.com. 2. National Cancer Register, Ireland, Cork, Ireland. 3. Department of Clinical Genetics, Our Lady's Children's Hospital, Crumlin, Ireland. 4. Department of Endocrinology, St. James's Hospital, Dublin 8, Ireland. 5. Department of Otolaryngology, Head and Neck Surgery, St. James's Hospital, Dublin 8, Ireland. 6. Department of Otolaryngology, Head and Neck Surgery, Beaumont Hospital, Dublin, Ireland.
Abstract
BACKGROUND AND OBJECTIVES: Medullary thyroid cancer consists of a spectrum of disease that ranges from extremely indolent tumors to aggressive types associated with a high mortality rate. The objective of our study is to evaluate the prognostic factors and outcomes of patients diagnosed with MTC in a homogenous population, and to examine patients diagnosed with MTC for mutations in the RET proto-oncogene from the same period. METHODS: A retrospective analysis of the National Cancer Registry in Ireland was undertaken, between 1998 and 2007. The Kaplan-Meier method was used to determine overall survival and factors predictive of outcome were determined by univariate and multivariate analysis by cox regression using Stata 13 software. MAIN FINDINGS: Forty-three patients were diagnosed with medullary thyroid cancer, 55.8 % were female and 44.2 % were male. A median age of 52 was found. The overall median survival was 6.32 years and the 1- and 5-year overall survival was 88.37 and 62.79 %, respectively, with 10-year survival calculated at 48.63 %. On univariate analysis age, stage and surgical intervention were statistically significant indicators of prognosis. T stage and age remained statistically significant indicators of prognosis on multivariate analysis. Two patients with no history of MEN syndromes or family history of medullary thyroid cancer had RET proto-onocogene mutations. CONCLUSIONS: Our patient cohort was substantially older and presented at an advanced T status than what is commonly seen in the literature. This may account for poor survival outcomes and the very low pick-up of RET mutations in sporadic medullary thyroid cancer.
BACKGROUND AND OBJECTIVES: Medullary thyroid cancer consists of a spectrum of disease that ranges from extremely indolent tumors to aggressive types associated with a high mortality rate. The objective of our study is to evaluate the prognostic factors and outcomes of patients diagnosed with MTC in a homogenous population, and to examine patients diagnosed with MTC for mutations in the RET proto-oncogene from the same period. METHODS: A retrospective analysis of the National Cancer Registry in Ireland was undertaken, between 1998 and 2007. The Kaplan-Meier method was used to determine overall survival and factors predictive of outcome were determined by univariate and multivariate analysis by cox regression using Stata 13 software. MAIN FINDINGS: Forty-three patients were diagnosed with medullary thyroid cancer, 55.8 % were female and 44.2 % were male. A median age of 52 was found. The overall median survival was 6.32 years and the 1- and 5-year overall survival was 88.37 and 62.79 %, respectively, with 10-year survival calculated at 48.63 %. On univariate analysis age, stage and surgical intervention were statistically significant indicators of prognosis. T stage and age remained statistically significant indicators of prognosis on multivariate analysis. Two patients with no history of MEN syndromes or family history of medullary thyroid cancer had RET proto-onocogene mutations. CONCLUSIONS: Our patient cohort was substantially older and presented at an advanced T status than what is commonly seen in the literature. This may account for poor survival outcomes and the very low pick-up of RET mutations in sporadic medullary thyroid cancer.
Entities:
Keywords:
Calcitonin; Cancer registry; Database; Medullary thyroid cancer; RET proto-oncogene; Survival
Authors: Emad Kandil; Marta M Gilson; Haytham H Alabbas; Anthony P Tufaro; Alan Dackiw; Ralph P Tufano Journal: Ann Surg Oncol Date: 2010-10-29 Impact factor: 5.344
Authors: M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx Journal: J Clin Endocrinol Metab Date: 2001-12 Impact factor: 5.958
Authors: Francesco Perri; Luciano Pezzullo; Maria Grazia Chiofalo; Secondo Lastoria; Francesca Di Gennaro; Giuseppina Della Vittoria Scarpati; Francesco Caponigro Journal: Crit Rev Oncol Hematol Date: 2014-11-01 Impact factor: 6.312
Authors: Herbert Chen; Rebecca S Sippel; M Sue O'Dorisio; Aaron I Vinik; Ricardo V Lloyd; Karel Pacak Journal: Pancreas Date: 2010-08 Impact factor: 3.327
Authors: Gregory W Randolph; Julie Ann Sosa; Yangyang Hao; Trevor E Angell; David C Shonka; Virginia A LiVolsi; Paul W Ladenson; Thomas C Blevins; Quan-Yang Duh; Ronald Ghossein; Mack Harrell; Kepal Narendra Patel; Michael H Shanik; S Thomas Traweek; P Sean Walsh; Michael W Yeh; Amr H Abdelhamid Ahmed; Allen S Ho; Richard J Wong; Joshua P Klopper; Jing Huang; Giulia C Kennedy; Richard T Kloos; Peter M Sadow Journal: Thyroid Date: 2022-08-08 Impact factor: 6.506